NPL

Across TCGA pan-cancer cohorts, NPL mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NPL data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NPL mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NPL expression acts as an unfavorable survival marker.

CCRCC, PDAC, and UCEC are the cancer types where NPL mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	0.404	1.000	.020	9	view →
PDAC	DFS	Quartile	II,III,IV	0.185	0.437	.009	9	view →
UCEC	DFS	Quartile	All	0.783	0.963	.019	6	view →
LUAD	OS	Tertile	III,IV	0.317	0.780	.027	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NPL–CCRCC (DFS)

Open the CCRCC breakdown →